...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Gran Oso.....

"..... would you mind to explain, once more, the importance of the withheld data and how it relates to the overall scheme of things?"

It's the CKD sub-study. We already know from disclosed data that apabetalone elicited amazing 50% MACE reduction in those patients with stage 3 CKD (baseline eGFR<60). We are waiting for the kidney function data (change in eGFR, etc). Big news if apabetalone elicits MACE reduction and improved eGFR in diabetics with CKD.

BDAZ

Share
New Message
Please login to post a reply